Is This Stock a Screaming Buy: Array BioPharma Inc. (NASDAQ:ARRY)

Equity Research firms currently have a positive stance on shares of Array BioPharma Inc. (NASDAQ:ARRY). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $9.43 on a short term basis.

At the time of writing, the stock was trading at $6.64. This represents a change from the opening price of -1.04%. In terms of performance, year to date, the stock is 58.29%. The monthly stock performance comes in at 85.56%. For the quarter, shares are performing at 80.05%. Weekly performance analysis shows the equity at 7.05%.

In taking a look at technical levels, shares are trading 59.35% away from the 50 day simple moving average and 90.92% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -8.67% away from it’s 52- week high and 178.99% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Array BioPharma Inc.’s RSI stands at 74.27. In looking at volatility levels, the shares saw weekly volatility of 6.81% and 8.26% over the past month.

Leave a Comment